Smith, Moore & Co. Gilead Sciences, Inc. Transaction History

Smith, Moore & Co.

$1.17 Billion
Q3 2025

A detailed history of Smith, Moore & Co. transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Smith, Moore & Co. holds 2,081 shares of GILD stock, worth $260,166. This represents 0.02% of its overall portfolio holdings.

Number of Shares

2,081

Previous 2,075 0.29%

Holding current value

$260,166

Previous $230,000 -0.0%

% of portfolio

0.02%

Previous 0.02%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 12, 2025	BUY	$108.22 - $120.47 $649 - $722	6 Added 0.29%	2,081 $230,000
Q2 2025 Aug 13, 2025	SELL	$96.91 - $113.0 $5,330 - $6,215	-55 Reduced 2.58%	2,075 $230,000
Q1 2025 May 14, 2025	SELL	$89.14 - $117.41 $89,140 - $117,410	-1,000 Reduced 31.95%	2,130 $238,000
Q4 2024 Feb 12, 2025	BUY	$83.95 - $97.9 $1,343 - $1,566	16 Added 0.51%	3,130 $289,000
Q3 2024 Nov 12, 2024	BUY	$66.59 - $83.99 $1,398 - $1,763	21 Added 0.68%	3,114 $261,000
Q2 2024 Aug 14, 2024	SELL	$63.15 - $72.88 $1,768 - $2,040	-28 Reduced 0.9%	3,093 $212,000
Q1 2024 May 10, 2024	BUY	$71.58 - $87.29 $15,389 - $18,767	215 Added 7.4%	3,121 $228,000
Q4 2023 Feb 13, 2024	SELL	$73.27 - $83.09 $1,025 - $1,163	-14 Reduced 0.48%	2,906 $235,000
Q3 2023 Nov 14, 2023	BUY	$73.94 - $80.67 $73 - $80	1 Added 0.03%	2,920 $218,000
Q2 2023 Aug 11, 2023	BUY	$76.01 - $86.7 $11,477 - $13,091	151 Added 5.46%	2,919 $224,000
Q4 2022 Feb 13, 2023	BUY	$62.32 - $89.47 $172,501 - $247,652	2,768 New	2,768 $237,000
Q4 2017 Feb 09, 2018	SELL	$71.15 - $83.52 $233,016 - $273,528	-3,275 Closed	0 $0
Q3 2017 Nov 02, 2017	BUY	$72.11 - $85.47 $236,160 - $279,914	3,275	3,275 $265,000

Others Institutions Holding GILD

# of Institutions

2,381

Shares Held

1.02B

Call Options Held

12.6M

Put Options Held

9.18M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $157B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Smith, Moore & Co., based on Form 13F filings with the SEC.

News

Stay updated on Smith, Moore & Co. with notifications on news.

Account